

Adolfo Favaretto

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1521372/adolfo-favaretto-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

87
papers

3,927
citations

28
h-index

61
g-index

90
ext. papers

4,468
ext. citations

5.5
avg. IF

4.29
L-index

#	Paper	IF	Citations
87	Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. <i>Journal of the National Cancer Institute</i> , 2003 , 95, 362-72	9.7	673
86	Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6865-72	2.2	394
85	Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1443-8	2.2	224
84	Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2667-74	2.2	200
83	First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3002-11	2.2	193
82	Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2017 , 5, 435-444	35.1	133
81	A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. <i>Nature Genetics</i> , 2014 , 46, 844-9	36.3	130
80	Long-term survival and prognostic factors in thymic epithelial tumours. <i>European Journal of Cardio-thoracic Surgery</i> , 2004 , 26, 412-8	3	105
79	Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2014 , 15, 1379-88	21.7	103
78	Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 4647-59	12.9	93
77	Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. <i>British Journal of Cancer</i> , 2008 , 99, 51-6	8.7	93
76	Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEMcitabine-COxib in NSCLC (GECO) study. <i>Lancet Oncology</i> , 2007 , 8, 500-12	21.7	80
75	Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis--a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study. <i>Journal of Clinical Oncology</i> , 2005 , 23, 569-75	2.2	77
74	Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. <i>British Journal of Cancer</i> , 2013 , 109, 552-8	8.7	75
73	Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4663-9	2.2	70
72	Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2018 , 36, 342-349	2.2	70
71	Long term results of surgery and chemotherapy in small cell lung cancer. <i>European Journal of Cardio-thoracic Surgery</i> , 1998 , 14, 398-402	3	60

70	Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. <i>Melanoma Research</i> , 2001 , 11, 189-96	3.3	55
69	Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study. <i>Journal of Clinical Oncology</i> , 2006 , 24, 681-7	2.2	49
68	NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 799-811	21.7	44
67	Platinum drugs and DNA repair mechanisms in lung cancer. <i>Anticancer Research</i> , 2014 , 34, 493-501	2.3	44
66	Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. <i>Annals of Oncology</i> , 2011 , 22, 1528-1534	10.3	42
65	Effects of sulfonyleureas on tumor growth: a review of the literature. <i>Oncologist</i> , 2013 , 18, 1118-25	5.7	38
64	Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial. <i>Journal of Thoracic Oncology</i> , 2007 , 2, 221-9	8.9	38
63	Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 97, 220-30	7	35
62	Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma. <i>Anticancer Research</i> , 2010 , 30, 5121-8	2.3	35
61	Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience. <i>BMC Research Notes</i> , 2012 , 5, 482	2.3	30
60	Long-term results of surgical management of pulmonary metastases from renal cell carcinoma. <i>Thoracic and Cardiovascular Surgeon</i> , 2006 , 54, 544-7	1.6	30
59	LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab. <i>Clinical Cancer Research</i> , 2017 , 23, 3316-3324	12.9	28
58	Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey. <i>British Journal of Cancer</i> , 2014 , 111, 220-6	8.7	28
57	A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 80-90	8.9	26
56	Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2014 , 15, 166-70	4.9	24
55	Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 733-7	8.9	24
54	Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors and new therapeutic perspectives in non small cell lung cancer. <i>Current Drug Targets</i> , 2011 , 12, 922-33	3	24
53	Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 665-72	8.9	22

52	Molecular targets in malignant pleural mesothelioma treatment. <i>Current Drug Targets</i> , 2009 , 10, 1235-44		22
51	Supportive care in patients with advanced non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2003 , 89, 1013-21	8.7	22
50	Cisplatin, etoposide, and ifosfamide in non-small cell lung carcinoma. A phase II randomized study with cisplatin and etoposide as the control arm. <i>Cancer</i> , 1990 , 65, 2631-4	6.4	22
49	Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study. <i>Lung Cancer</i> , 2008 , 60, 240-5	5.9	21
48	Granulocyte-macrophage colony-stimulating factor increases dose intensity of chemotherapy in small cell lung cancer. Relationship between clinical results, peripheral blood cell modifications, and bone marrow kinetics. <i>Cancer</i> , 1993 , 72, 697-706	6.4	20
47	An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesothelioma. <i>Cancer Treatment Reviews</i> , 2013 , 39, 10-7	14.4	18
46	Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens. <i>Critical Reviews in Oncology/Hematology</i> , 2004 , 51, 171-89	7	18
45	The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy. <i>Oncotarget</i> , 2013 , 4, 1572-81	3.3	18
44	Treatment of Unfit Patients With Advanced Non-Small-Cell Lung Cancer: Definition Criteria According an Expert Panel. <i>Clinical Lung Cancer</i> , 2015 , 16, 399-405	4.9	17
43	Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 1830-1844	8.9	17
42	Role of genotyping in non-small cell lung cancer treatment: current status. <i>Drugs</i> , 2011 , 71, 2231-46	12.1	17
41	Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer. <i>BMC Cancer</i> , 2016 , 16, 312	4.8	17
40	The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 994-1002	6.1	17
39	Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: final results of an International randomized phase II study (NAVotrial 01). <i>Clinical Lung Cancer</i> , 2014 , 15, 258-65	4.9	16
38	Overview on ongoing or planned clinical trials in Europe. <i>Lung Cancer</i> , 2005 , 49 Suppl 1, S117-21	5.9	16
37	Ultrarapid high-dose course of prophylactic cranial irradiation in small-cell lung cancer: evaluation of late neurologic morbidity in 16 long-term survivors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1998 , 21, 84-90	2.7	16
36	Results of surgical resection after induction chemoradiation for Pancoast tumours □ <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2015 , 20, 805-11; discussion 811-2	1.8	14
35	Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2014 , 19, 256-62; discussion 262	1.8	14

34	Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trials. <i>Lung Cancer</i> , 2012 , 76, 457-64	5.9	14
33	Second and third responses to the same induction regimen in relapsing patients with multiple myeloma. <i>Cancer</i> , 1991 , 68, 975-80	6.4	14
32	Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations. <i>Oncotarget</i> , 2017 , 8, 32626-32638	3.3	14
31	Bone marrow myeloid cell kinetics during treatment of small cell carcinoma of the lung with chemotherapy not associated and associated with granulocyte-macrophage colony-stimulating factor. <i>Annals of Hematology</i> , 1993 , 66, 185-93	3	12
30	Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience. <i>Lung Cancer</i> , 2011 , 73, 351-5	5.9	10
29	Effect of induction chemotherapy on lung function and exercise capacity in patients affected by malignant pleural mesothelioma. <i>European Journal of Cardio-thoracic Surgery</i> , 2010 , 37, 1464-9	3	10
28	HLA-G 3'UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	9
27	Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin's disease. <i>Acta Haematologica</i> , 2004 , 112, 141-7	2.7	9
26	MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data. <i>Oncotarget</i> , 2015 , 6, 42053-66	3.3	9
25	Synergistic antitumor activity of recombinant human Apo2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in combination with carboplatin and pemetrexed in malignant pleural mesothelioma. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 1008-1017	8.9	8
24	Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covid19 study. <i>European Journal of Cancer</i> , 2021 , 147, 120-127	7.5	8
23	Morphological and genetic heterogeneity in multifocal lung adenocarcinoma: The case of a never-smoker woman. <i>Lung Cancer</i> , 2016 , 96, 52-5	5.9	7
22	Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014 , 140, 1783-93	4.9	7
21	Non-Small Cell Lung Cancer in a Very Young Woman: A Case Report and Critical Review of the Literature. <i>American Journal of Case Reports</i> , 2015 , 16, 782-9	1.3	7
20	Second and third line treatment in non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2009 , 71, 117-26	7	7
19	Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer: A phase II trial. <i>Cancer</i> , 1996 , 78, 1701-1707	6.4	7
18	Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program. <i>Future Oncology</i> , 2018 , 14, 1347-1354	3.6	7
17	Epirubicin, methotrexate and bleomycin in the management of recurrent squamous cell head and neck cancer. A GSTTC randomised phase II study. <i>European Journal of Cancer</i> , 1993 , 29A, 704-8	7.5	6

16	A pilot study of concomitant radiation and chemotherapy in patients with locally advanced head and neck cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1993 , 16, 264-7	2.7	6
15	Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization. <i>Oncotarget</i> , 2016 , 7, 25050-63	3.3	6
14	Preoperative concomitant chemo-radiotherapy in superior sulcus tumour: A mono-institutional experience. <i>Lung Cancer</i> , 2010 , 68, 228-33	5.9	5
13	Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy. <i>Current Clinical Pharmacology</i> , 2018 , 13, 76-84 ²⁻⁵		5
12	Pemetrexed plus carboplatin or cisplatin as neoadjuvant treatment of operable malignant pleural mesothelioma (MPM). <i>Anticancer Research</i> , 2012 , 32, 5393-9	2.3	5
11	Phase I-II trial of gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly patients with performance status 0-2: the G-STEP trial. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 233-42	8.9	4
10	A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy. <i>Frontiers in Pharmacology</i> , 2018 , 9, 1101	5.6	4
9	Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC. <i>Lung Cancer</i> , 2016 , 100, 30-37	5.9	3
8	From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for -Positive Non-Small Cell Lung Cancer (MOST Study). <i>Oncologist</i> , 2019 , 24, e318-e326 ⁵⁻⁷		3
7	Valutazione economica in base allo studio NAVoTRIAL01 con riferimento al contesto sanitario italiano: Vinorelbine orale e Cisplatino o Pemetrexed e Cisplatino seguiti da mantenimento rispettivamente con Vinorelbine orale e Pemetrexed nel trattamento del Carcinoma Polmonare Non a Piccole Cellule Non Squamoso (NS-NSCLC) in stadio avanzato. <i>Pharmacoeconomics Italian</i>		2
6	Changes in pulmonary function tests predict radiological response to chemotherapy in malignant pleural mesothelioma. <i>European Journal of Cardio-thoracic Surgery</i> , 2013 , 44, 104-10	3	2
5	EAGLES study: First-line Bevacizumab in Combination with Chemotherapy in Elderly Patients with Advanced, Metastatic, Non-squamous Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2017 , 37, 2457-2464 ^{2,3}		2
4	Radiological response and survival in locally advanced non-small-cell lung cancer patients treated with three-drug induction chemotherapy followed by radical local treatment. <i>OncoTargets and Therapy</i> , 2016 , 9, 3671-81	4.4	2
3	Epirubicin plus paclitaxel regimen as second-line treatment of patients with small-cell lung cancer. <i>Anticancer Research</i> , 2015 , 35, 2183-9	2.3	2
2	Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020-Sep 2020; Sep 2020-May 2021) in the Veneto Oncology Network: The ROVID study.. <i>European Journal of Cancer</i> , 2022 , 167, 81-91	7.5	0
1	Bevacizumab combined with pemetrexed plus cisplatin followed by maintenance bevacizumab/pemetrexed as first-line treatment of advanced non-squamous non-small cell lung cancer: A single-arm Phase 2 study. <i>Lung Cancer</i> , 2014 , 86, 47-53	5.9	